Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Drug Target Review
drugtargetreview.com > oral-antiviral-ghp-88310-candidate-shown-to-block-measles-transmission-in-ferret-model > 2136071.article

Oral antiviral GHP-88310 candidate shown to block measles transmission in ferret model

1+ day, 18+ hour ago   (552+ words) New research shows that a viral polymerase inhibitor developed at Georgia State University, named GHP-88310, can block canine distemper virus transmission in ferrets under conditions designed to mimic real-world measles spread – which could inform new outbreak response strategies. A new…...

Drug Target Review
drugtargetreview.com > 3d-genome-reorganisation-identified-as-alzheimers-disease-molecular-hallmark > 2136069.article

3D genome reorganisation identified as Alzheimer’s disease molecular hallmark

1+ day, 20+ hour ago   (408+ words) Researchers have used the GAGE-seq technique and an AI model called Hicformer to demonstrate that the three-dimensional folding of the genome is significantly disrupted in brain cells affected by Alzheimer’s disease – a finding that could help prioritise new targets for…...

Drug Target Review
drugtargetreview.com > insilico-medicine-nominates-ism9528-non-opioid-chronic-pain-candidate-using-ai > 2136066.article

Insilico Medicine nominates ISM9528 non-opioid chronic pain candidate using AI

2+ day, 17+ hour ago   (452+ words) Insilico Medicine has announced ISM9528, a potential first-in-class non-opioid therapy for chronic pain, has demonstrated superior preclinical efficacy to morphine and pregabalin and a favourable safety profile. Insilico used its PandaOmics artificial intelligence platform to identify and prioritise a previously unrecognised…...

Drug Target Review
drugtargetreview.com > elrig-appoints-two-industry-veterans-to-their-scientific-advisory-board > 2136060.article

ELRIG appoints two industry veterans to their Scientific Advisory Board

2+ day, 21+ hour ago   (260+ words) ELRIG has expanded its Scientific Advisory Board with two senior appointments, drawing on more than 50 years of combined drug discovery experience to guide the organisation’s strategic direction and conference programming. ELRIG has strengthened its Scientific Advisory Board (SAB) with the…...

Drug Target Review
drugtargetreview.com > home > making-historical-toxicology-data-work-harder-in-safety-assessment > 2136057.article

Making historical toxicology data work harder in safety assessment

3+ day, 17+ min ago   (1098+ words) Drug developers have generated decades of toxicology data and insights, but much of it remains underused. Laura Lotfi of Charles River Laboratories discusses how Virtual Control Groups and AI could help put that information to work. Safety assessment is a…...

Drug Target Review
drugtargetreview.com > new-drug-target-identified-to-protect-hearts-in-dmd-patients > 2136038.article

New drug target identified to protect hearts in DMD patients

3+ day, 18+ hour ago   (550+ words) A new preclinical study has shown that Setanaxib, an inhibitor of the oxidative stress enzymes NOX1 and NOX4, preserved cardiac function and reduced fibrosis in two models of Duchenne muscular dystrophy. Researchers at the University of South Florida (USF) Health Morsani College…...

Drug Target Review
drugtargetreview.com > webinars > meeting-ethical-and-regulatory-requirements-when-using-human-biological-specimens > 2136000.article

Meeting ethical & regulatory requirements when using human biological specimens

3+ day, 20+ hour ago   (371+ words) Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research. In this webinar, BioIVT’s Compliance & Regulatory Affairs (C…...

Drug Target Review
drugtargetreview.com > new-bispecific-t-cell-engager-platform-targets-ovarian-cancer-in-preclinical-studies > 2136026.article

New bispecific T cell engager platform targets ovarian cancer in preclinical studies

3+ day, 21+ hour ago   (287+ words) A novel bispecific T cell engager combining precision antibody engineering with an in vivo DNA delivery platform has shown improved tumour-killing activity and extended half-life in preclinical ovarian cancer studies. Scientists at The Wistar Institute have developed a new form…...

Drug Target Review
drugtargetreview.com > tumour-organoids-may-expand-access-to-targeted-cancer-drugs > 2136007.article

Tumour organoids may expand access to targeted cancer drugs

4+ day, 17+ hour ago   (563+ words) Researchers have developed a library of 220 patient-derived tumour organoids spanning 15 cancer types, demonstrating their long-term fidelity as preclinical models and their capacity to replicate the tumour immune microenvironment. Significant developments in the creation of new patient-derived tumour organoids could lead…...

Drug Target Review
drugtargetreview.com > home > how-ai-and-human-biology-data-led-to-a-new-addiction-drug-candidate > 2135999.article

How AI and human biology data led to a new addiction drug candidate

4+ day, 21+ hour ago   (1107+ words) Can AI help researchers identify better drug candidates before they reach the laboratory? New research in opioid use disorder (OUD) suggests that combining human-derived biology with AI could improve how therapeutic targets and drug candidates are selected. Choosing the right…...